InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Friday, 06/21/2019 1:40:37 PM

Friday, June 21, 2019 1:40:37 PM

Post# of 253
News: $CATB Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative effects of the corticosteroid prednisolone in a mouse model of Duchenne muscular dystrophy...

In case you are interested https://marketwirenews.com/news-releases/catabasis-pharmaceuticals-presents-preclinical-data-showing-potential-for-bone-preservation-with-edasalonexent-in-duchenne-muscular-dystrophy-8395012.html